Sunday, September 27, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 3, 2026

Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts

View original at finance.yahoo.com
Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts Quick Read Novo Nordisk (NVO) cut Wegovy and Ozempic prices up to 48% in India due to generic semaglutide competition, while shares have fallen 43% over the past year to $36.98 as 2026 guidance signals -5% to -13% adjusted sales growth; the c…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Wegovy HD achieved an average weight loss of 20.7% over 72 weeks

    60% confidence

  • 2026 guidance signals -5% to -13% adjusted sales growth

    60% confidence

  • CagriSema (cagrilintide plus semaglutide) is expected to receive FDA obesity decision around end of 2026/early 2027

    60% confidence

  • Phase 3 data showed 14.2% weight loss in type 2 diabetes patients for CagriSema

    60% confidence

Data points we hold from this source

Novo Nordisk · stock price 52 week low35.12 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts — Source | Via News | Via News